Cytospire is developing an innovative portfolio of differentiated multispecific engager antibodies to enhance and direct the activity of innate and adaptive effector immune cells. Our core technology allows binding and activation of both tissue/tumour and blood resident gamma delta T cells. This opens a path to safer and more efficacious targeting of well-validated antigens that are intractable to CD3 T cell engagers due to toxicity. There are broad opportunities for Cytospire’s gamma delta T cell engagers in solid and haematological malignancies, as well as in autoimmune disease.
Cytospire Therapeutics: Venture Capital Funding History
Cytospire Therapeutics
Cytospire Therapeutics
- Life Sciences
- London, United Kingdom
- £61m
- cytospire.com
- Update Information
More venture news
- 13 Nov 2026

Oyster TherapeuticsOyster Therapeutics secures a £45m Series A round from CE-Ventures to develop an oral drug for neurodegenerative diseases
Series ALife Sciences - 10 Nov 2026

Neobe TherapeuticsNeobe lands a £5m seed round led by ARC Ventures to deliver cancer drugs directly into solid tumours
SeedLife Sciences - 9 Nov 2026

PhaSER BiomedicalPhaSER Biomedical secures a £2m grant from Gates Foundation to discover new treatments for neglected diseases
GrantLife Sciences
